Biodel to Report Fourth Quarter Fiscal Year 2010 Financial Results on December 9, 2010

DANBURY, Conn., Dec. 6, 2010 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) will issue its fourth quarter fiscal year 2010 financial results on December 9, 2010. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.

December 9, 2010 schedule:



4:00 pm EST:

Q4 fiscal year 2010 results will be


distributed



4:15 pm EST:

Conference call participants should dial:


+1 ( 877 ) 303 - 8028 (United States) or


+1 ( 760 ) 536 - 5167 (International)



4:30 pm EST:

Conference call begins



Interested parties may access a live audio webcast of the conference call in the investor section of Biodel's website at http://www.biodel.com. The audio webcast will be archived and available for replay through the website.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel's product candidates are developed using VIAdel™ technology, which reformulates existing FDA-approved peptide drugs. Linjeta™ is Biodel's most advanced product candidate and has been reviewed by the FDA which issued a complete response letter. Earlier-stage product candidates include VIAtab™, a sublingual tablet formulation of insulin, a line of basal insulins, and a stabilized formulation of glucagon. For further information regarding Biodel, please visit the company's website at www.biodel.com.

BIOD-G

The Trout Group LLC

Seth D. Lewis, +1-646-378-2952



SOURCE Biodel Inc.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.